Centre Hospitalier Universitaire de Caen Normandie

Running trials

• Not yet recruiting

  Efanesoctocog Prophylaxis Or The Optimization Of Treatment: Real-World Experience Of Taylorizing Clotting Therapy In Hemophilia A

  NCT07830693· Nantes University Hospital· Source

• Not yet recruiting

  Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)

  NCT07890012· Hospices Civils de Lyon· Source

• Not yet recruiting

  Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

  NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source

• Not yet recruiting

  Analysis of histological risk factors and biomarkers in paediatric retinoblastoma

  2024-515962-15-00· Phase 2· Institut Curie· Source

• Not yet recruiting

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

  NCT07924384· Institut Curie· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  Impact on Delirium of the Use of DEXmedetomidine as First-line Sedation in PEDIAtric Intensive Care

  NCT07542990· Phase 3· University Hospital, Tours· Source

• Not yet recruiting

  Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer

  NCT07759492· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Not yet recruiting

  Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

  NCT07644377· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial

  NCT07818356· Phase 4· University Hospital, Toulouse· Source

• Not yet recruiting

  Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab

  NCT07836283· Phase 3· University Hospital, Rouen· Source

• Not yet recruiting

  Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes

  NCT07401901· Medtronic MiniMed, Inc.· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Not yet recruiting

  Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial

  2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source

• Not yet recruiting

  ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.

  NCT07737964· Phase 3· University Hospital, Montpellier· Source

• Recruiting

  A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

  NCT07751991· Phase 1· Charm Therapeutics· Source

• Recruiting

  ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

  NCT07545512· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

  NCT07420439· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Not yet recruiting

  Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial

  NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer

  NCT07241273· UNICANCER· Source

• Not yet recruiting

  Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2

  2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source

• Recruiting

  Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults

  NCT07358000· University Hospital, Caen· Source

• Not yet recruiting

  OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.

  2025-524003-68-00· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Not yet recruiting

  Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease

  NCT07498309· Phase 3· University Hospital, Rouen· Source

• Not yet recruiting

  Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial

  2025-521493-33-00· Phase 3· Centre Hospitalier Intercommunal Creteil· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  IMpact of Mind-body Therapies (HYpnosis and Relaxation) on Anxiety in Children, Adolescents and Young Adults Who Had Been Treated in ONcology. Multicenter Study.

  NCT07380672· Centre Hospitalier Universitaire de Saint Etienne· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

  2024-519753-11-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Not yet recruiting

  Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE)

  NCT07132164· University Hospital, Brest· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

• Active, not recruiting

  A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

  2023-503298-39-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients

  NCT07771855· Phase 2· Hopital Foch· Source

• Not yet recruiting

  Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicenter Randomized Controlled Trial (IVT-ALL-IN)

  NCT07603440· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

  NCT07189325· Phase 3· University Hospital, Montpellier· Source

• Recruiting

  Influence of Therapeutic Failure on the Psychosocial Experience in Multiple Sclerosis

  NCT07372599· University Hospital, Caen· Source

• Recruiting

  CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.

  2025-523264-21-00· Phase 2/3· Institut National De La Sante Et De La Recherche Medicale· Source

• Not yet recruiting

  Bosentan in the Treatment of Giant Cell Arteritis

  NCT06957002· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  DOXYCYCLINE PENETRATION INTO BONE AND JOINT.

  2025-524744-36-00· Phase 2· Centre Hospitalier Universitaire De Caen Normandie· Source

• Not yet recruiting

  Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor

  NCT07471425· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source

• Recruiting

  Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

  NCT07418827· Assistance Publique Hopitaux De Marseille· Source

• Recruiting

  Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

  NCT07292012· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

  NCT07245680· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

Showing 50 of 320.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers29 recruiting
• Lung cancer16 recruiting
• Acute myeloid leukaemia15 recruiting
• Multiple myeloma11 recruiting
• Stroke11 recruiting
• Acute lymphoblastic leukaemia8 recruiting
• Heart failure6 recruiting
• Multiple sclerosis6 recruiting
• Neuroendocrine tumours6 recruiting
• Pancreatic cancer6 recruiting
• Atrial fibrillation5 recruiting
• Colorectal cancer5 recruiting
• Coronary artery disease5 recruiting
• Giant cell arteritis5 recruiting
• Idiopathic pulmonary fibrosis5 recruiting
• Crohn's disease4 recruiting
• Head and neck cancer4 recruiting
• High blood pressure4 recruiting
• Sarcoma4 recruiting
• Systemic sclerosis (scleroderma)4 recruiting
• Asthma3 recruiting
• Atopic dermatitis (eczema)3 recruiting
• Brain aneurysm3 recruiting
• Chronic kidney disease3 recruiting
• Kidney cancer3 recruiting
• Lupus (SLE)3 recruiting
• Rheumatoid arthritis3 recruiting
• Sjögren's disease3 recruiting
• Alzheimer disease2 recruiting
• Ankylosing spondylitis2 recruiting
• Aplastic anaemia2 recruiting
• Bronchiectasis2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Chronic myeloid leukaemia2 recruiting
• COPD2 recruiting
• Cystic fibrosis2 recruiting
• Deep vein thrombosis and pulmonary embolism2 recruiting
• Endometriosis2 recruiting
• Haemophilia2 recruiting
• HIV2 recruiting
• Irritable bowel syndrome2 recruiting
• Liver and biliary tract cancer2 recruiting
• Mesothelioma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Neuroblastoma2 recruiting
• Osteoarthritis2 recruiting
• Ovarian cancer2 recruiting
• Parkinson disease2 recruiting
• Polymyalgia rheumatica2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Type 1 diabetes2 recruiting
• Type 2 diabetes2 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic stenosis1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Depression1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diabetic foot ulcer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gastroparesis1 recruiting
• Gout1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lewy body dementia1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Narcolepsy1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoporosis1 recruiting
• Psoriasis1 recruiting
• Sarcoidosis1 recruiting
• Schizophrenia1 recruiting
• Sickle cell disease1 recruiting
• Thymoma and thymic carcinoma1 recruiting
• Ulcerative colitis1 recruiting
• Uterine fibroids1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Not yet recruiting

  Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

  NCT05651880· Phase 3· University Hospital, Rouen· Source

• Withdrawn

  Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

  NCT07039422· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma

  NCT05896163· Phase 1/2· Pfizer Inc.· Source

• Completed

  Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database

  NCT06902441· University Hospital, Caen· Source

• Completed

  IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reach at least a very good partial response with their previous treatment

  NCT05066607· Phase 2· Intergroupe Francophone Du Myelome· Source

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source

• Completed

  ALS Phase II Study of NX210c

  NCT06365216· Phase 2· Axoltis Pharma· Source

• Completed

  A safety study of PF-08046044/SGN-35C in adults with advanced cancers

  NCT06254495· Phase 1· Seagen Inc.· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  NCT06332534· Phase 3· AbbVie· Source

• Completed

  Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy

  2023-509615-92-00· Phase 2· Hopital Fondation Adolphe De Rothschild· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Completed

  Safety and Efficacy Assessments of NeoKidney® in ESRD Patients Treated With Short Daily Hemodialysis

  NCT06024135· Nextkidney S.A.· Source

• Completed

  Real-life Follow-up of the Physical Activity in Type 1 Diabetes Participants Equipped With an Insulin Pump With Hybrid Closed Loop

  NCT07015970· ISIS Diabete Service· Source

• Completed

  A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to test the effect of brigatinib after standard chemotherapy and radiation therapy is completed.

  NCT05718297· Phase 2· ETOP IBCSG Partners Foundation· Source

• Completed

  A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC

  2022-503007-22-00· Phase 2· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  Prevalence of Ascending Aortic Dilation in Sports Medicine

  NCT07050953· University Hospital, Caen· Source

• Active, not recruiting

  A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

  NCT06099782· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Pulsed Field Ablation vs Cryoablation In Paroxysmal Atrial Fibrillation

  NCT05940597· University Hospital, Grenoble· Source

• Terminated

  Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

  NCT05609942· Phase 1· Blueprint Medicines Corporation· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Completed

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· Phase 4· Swedish Orphan Biovitrum AB (publ)· Source

• Completed

  A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.

  2022-500275-31-00· Phase 3· Swedish Orphan Biovitrum AB (publ)· Source

• Active, not recruiting

  Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

  NCT05673187· Phase 2· ETOP IBCSG Partners Foundation· Source

• Completed

  Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn's Disease with an Inadequate Response to Conventional Therapy

  2023-508777-91-00· Phase 2/3· Celgene International II S.a.r.l.· Source

• Completed

  PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy-

  2022-501217-31-00· Phase 2/3· Fondation Franc.Cancerologie Digestive· Source

• Recruiting

  Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

  NCT04789850· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  PortoSinusoidal Vascular Diseases and Systemic Sclerosis

  NCT06032754· University Hospital, Caen· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period

  2023-509078-45-00· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER

  NCT05448677· Phase 2· Centre Hospitalier Universitaire De Grenoble· Source

• Completed

  A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus

  NCT05306574· Phase 3· Remegen Co. Ltd.· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT

  NCT05524324· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Partial Nephrectomy in Low Pressure

  NCT05404685· University Hospital, Bordeaux· Source

• Completed

  A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

  NCT05499130· Phase 2· Teva Branded Pharmaceutical Products R&D, Inc.· Source

• Terminated

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

  NCT05255601· Phase 1/2· Bristol-Myers Squibb· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· United Therapeutics· Source

• Completed

  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

  NCT05083182· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

  NCT05403385· Phase 2· iTeos Therapeutics· Source

• Completed

  Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05350072· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Completed

  Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)

  NCT05030155· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

  NCT05308966· Groupe Francais De Pneumo-Cancerologie· Source

• Withdrawn

  Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)

  NCT05074147· Phase 3· Tourcoing Hospital· Source

• Completed

  Objective and Perceived Health Status of Elderly People With Moderate or Severe Haemophilia in France: an Ancillary Study of the FranceCoag Registry

  NCT05218772· Assistance Publique Hopitaux De Marseille· Source

• Completed

  Tamibarotene/Venetoclax/Azacitidine in Previously Untreated Patients Selected for RARA-positive AML (SELECT-AML-1)

  NCT04905407· Phase 2· Syros Pharmaceuticals Inc.· Source

• Completed

  AcTIVE - ACid tranexamic or Terlipressin for Initial emergency treatment of mild to seVere hEmoptysis: a randomized Trial

  NCT04961528· Phase 3· Assistance Publique Hopitaux De Paris· Source

Showing 50 of 129.

Conditions

Diseases this institution publishes on or runs trials for.

• Ventricular tachycardia9 works · 1 trial
• Giant cell arteritis9 works · 7 trials
• Haemophilia6 works · 11 trials
• Immune thrombocytopenia (ITP)5 works · 5 trials
• ANCA-associated vasculitis4 works · 3 trials